nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.09.2008

Molecular markers of radiation-related normal tissue toxicity

verfasst von: Paul Okunieff, Yuhchyau Chen, David J. Maguire, Amy K. Huser

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Over the past five decades, those interested in markers of radiation effect have focused primarily on tumor response. More recently, however, the view has broadened to include irradiated normal tissues—markers that predict unusual risk of side-effects, prognosticate during the prodromal and therapeutic phases, diagnose a particular toxicity as radiation-related, and, in the case of bioterror, allow for tissue-specific biodosimetry. Currently, there are few clinically useful radiation-related biomarkers. Notably, levels of some hormones such as thyroid-stimulating hormone (TSH) have been used successfully as markers of dysfunction, indicative of the need for replacement therapy, and for prevention of cancers. The most promising macromolecular markers are cytokines: TGFβ, IL-1, IL-6, and TNFα being lead molecules in this class as both markers and targets for therapy. Genomics and proteomics are still in nascent stages and are actively being studied and developed.

Radford, I. R. (1986). Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. International Journal of Radiation Biology, 49(4), 611–620.CrossRef

Chapman, J. D., & Allalunis-Turner, M. J. (1991). Cellular and molecular targets in normal tissue radiation injury. In P. H. Gutin, S. A. Liebel, & G. E. Sheline (Eds.) Radiation injury to the nervous system (pp. 1–16). New York: Raven.

Anscher, M. S., Crocker, I. R., & Jirtle, R. L. (1990). Transforming growth factor-beta 1 expression in irradiated liver. Radiation Research, 122(1), 77–85.PubMedCrossRef

Finkelstein, J. N., Johnston, C. J., Baggs, R., & Rubin, P. (1994). Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis. International Journal of Radiation Oncology, Biology, Physics, 28(3), 621–631.PubMed

Piguet, P. F. (1990). Is “tumor necrosis factor” the major effector of pulmonary fibrosis? European Cytokine Network, 1(4), 257–258.PubMed

Rubin, P., Johnston, C. J., Williams, J. P., McDonald, S., & Finkelstein, J. N. (1995). A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. International Journal of Radiation Oncology, Biology, Physics, 33(1), 99–109.PubMed

McBride, W. H. (1995). Cytokine cascades in late normal tissue radiation responses. International Journal of Radiation Oncology, Biology, Physics, 33(1), 233–234.PubMed

Stone, H. B., Coleman, C. N., Anscher, M. S., & McBride, W. H. (2003). Effects of radiation on normal tissue: Consequences and mechanisms. Lancet Oncology, 4(9), 529–536.PubMedCrossRef

Kruse, J. J., & Stewart, F. A. (2007). Gene expression arrays as a tool to unravel mechanisms of normal tissue radiation injury and prediction of response. World Journal of Gastroenterology, 13(19), 2669–2674.PubMed

10.

Fleckenstein, K., Gauter-Fleckenstein, B., Jackson, I. L., Rabbani, Z., Anscher, M., & Vujaskovic, Z. (2007). Using biological markers to predict risk of radiation injury. Seminars in Radiation Oncology, 17(2), 89–98.PubMedCrossRef

11.

Hartsell, W. F., Scott, C. B., Dundas, G. S., Mohiuddin, M., Meredith, R. F., Rubin, P., et al. (2007). Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. American Journal of Clinical Oncology, 30(4), 368–376.PubMedCrossRef

12.

Brush, J., Lipnick, S. L., Phillips, T., Sitko, J., McDonald, J. T., & McBride, W. H. (2007). Molecular mechanisms of late normal tissue injury. Seminars in Radiation Oncology, 17(2), 121–130.PubMedCrossRef

13.

Stone, H. B., Moulder, J. E., Coleman, C. N., Ang, K. K., Anscher, M. S., Barcellos-Hoff, M. H., et al. (2004). Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3–4, 2003. Radiation Research, 162(6), 711–728.PubMedCrossRef

14.

Al Rashid, S. T., Dellaire, G., Cuddihy, A., Jalali, F., Vaid, M., Coackley, C., et al. (2005). Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Research, 65(23), 10810–10821.PubMedCrossRef

15.

Yu, T., MacPhail, S. H., Banath, J. P., Klokov, D., & Olive, P. L. (2006). Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair, 5(8), 935–946.PubMedCrossRef

16.

Klokov, D., MacPhail, S. M., Banath, J. P., Byrne, J. P., & Olive, P. L. (2006). Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiotherapy and Oncology, 80(2), 223–229.PubMedCrossRef

17.

West, C. M., Elliott, R. M., & Burnet, N. G. (2007). The genomics revolution and radiotherapy. Clinical Oncology (Royal College of Radiology, 19(6), 470–480.

18.

Fernet, M., & Hall, J. (2004). Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair, 3(8–9), 1237–1243.PubMedCrossRef

19.

Meyer, A., John, E., Dork, T., Sohn, C., Karstens, J. H., & Bremer, M. (2004). Breast cancer in female carriers of ATM gene alterations: Outcome of adjuvant radiotherapy. Radiotherapy and Oncology, 72(3), 319–323.PubMedCrossRef

20.

Andreassen, C. N. (2005). Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? Acta Oncológica, 44(8), 801–815.PubMedCrossRef

21.

Wichers, M., & Maes, M. (2002). The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. International Journal of Neuropsychopharmacology, 5(4), 375–388.PubMedCrossRef

22.

Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K., & Morrow, G. R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12(Suppl 1), 22–34.PubMedCrossRef

23.

Okunieff, P., Augustine, E., Hicks, J. E., Cornelison, T. L., Altemus, R. M., Naydich, B. G., et al. (2004). Pentoxifylline in the treatment of radiation-induced fibrosis. Journal of Clinical Oncology, 22(11), 2207–2213.PubMedCrossRef

24.

Daigle, J. L., Hong, J. H., Chiang, C. S., & McBride, W. H. (2001). The role of tumor necrosis factor signaling pathways in the response of murine brain to irradiation. Cancer Research, 61(24), 8859–8865.PubMed

25.

Noble, M., & Dietrich, J. (2002). Intersections between neurobiology and oncology: Tumor origin, treatment and repair of treatment-associated damage. Trends in Neurosciences, 25(2), 103–107.PubMedCrossRef

26.

Fike, J. R., Rola, R., & Limoli, C. L. (2007). Radiation response of neural precursor cells. Neurosurgery Clinics of North America, 18(1), 115–127.PubMedCrossRef

27.

Siman, R., Zhang, C., Roberts, V. L., Pitts-Kiefer, A., & Neumar, R. W. (2005). Novel surrogate markers for acute brain damage: Cerebrospinal fluid levels correlate with severity of ischemic neurodegeneration in the rat. Journal of Cerebral Blood Flow and Metabolism, 25(11), 1433–1444.PubMedCrossRef

28.

Guan, W., Yang, Y. L., Xia, W. M., Li, L., & Gong, D. S. (2003). Significance of serum neuron-specific enolase in patients with acute traumatic brain injury. Chinese Journal of Traumatology, 6(4), 218–221.PubMed

29.

McDonald, S., Meyerowitz, C., Smudzin, T., & Rubin, P. (1994). Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. International Journal of Radiation Oncology, Biology, Physics, 29(4), 747–754.PubMed

30.

Burlage, F. R., Roesink, J. M., Kampinga, H. H., Coppes, R. P., Terhaard, C., Langendijk, J. A., et al. (2008). Protection of salivary function by concomitant pilocarpine during radiotherapy: A double-blind, randomized, placebo-controlled study. International Journal of Radiation Oncology, Biology, Physics, 70(1), 14–22 Sep 14.PubMed

31.

Thula, T. T., Schultz, G., Tran-Son-Tay, R., & Batich, C. (2005). Effects of EGF and bFGF on irradiated parotid glands. Annals of Biomedical Engineering, 33(5), 685–695.PubMedCrossRef

32.

Beaven, A. W., & Shea, T. C. (2007). Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. Drugs of Today (Barcelona, Spain), 43(7), 461–473.CrossRef

33.

Dubray, B., Girinski, T., Thames, H. D., Becciolini, A., Porciani, S., Hennequin, C., et al. (1992). Post-irradiation hyperamylasemia as a biological dosimeter. Radiotherapy and Oncology, 24(1), 21–26.PubMedCrossRef

34.

Farrell, C. L., Bready, J. V., Rex, K. L., Chen, J. N., DiPalma, C. R., Whitcomb, K. L., et al. (1998). Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Research, 58(5), 933–939.PubMed

35.

Farrell, C. L., Rex, K. L., Chen, J. N., Bready, J. V., DiPalma, C. R., Kaufman, S. A., et al. (2002). The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Proliferation, 35(Suppl 1), 78–85.PubMedCrossRef

36.

Rubin, P., Finkelstein, J. N., Siemann, D. W., Shapiro, D. L., Van Houtte, P., & Penney, D. P. (1986). Predictive biochemical assays for late radiation effects. International Journal of Radiation Oncology, Biology, Physics, 12(4), 469–476.PubMed

37.

Rubin, P., McDonald, S., Maasilta, P., Finkelstein, J. N., Shapiro, D. L., Penney, D., et al. (1989). Serum markers for prediction of pulmonary radiation syndromes. Part I: Surfactant apoprotein. International Journal of Radiation Oncology, Biology, Physics, 17(3), 553–558.PubMed

38.

Gross, N. J. (1991). Surfactant subtypes in experimental lung damage: Radiation pneumonitis. American Journal of Physiology, 260(4 Pt 1), L302–L310.PubMed

39.

Chen, Y., Rubin, P., Williams, J., Hernady, E., Smudzin, T., & Okunieff, P. (2001). Circulating IL-6 as a predictor of radiation pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 49(3), 641–648.PubMed

40.

Chen, Y., Hyrien, O., Williams, J., Okunieff, P., Smudzin, T., & Rubin, P. (2005). Interleukin (IL)-1A and IL-6: Applications to the predictive diagnostic testing of radiation pneumonitis. International Journal of Radiation Oncology, Biology, Physics, 62(1), 260–266.PubMedCrossRef

41.

Evans, E. S., Kocak, Z., Zhou, S. M., Kahn, D. A., Huang, H., Hollis, D. R., et al. (2006). Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer? Cytokine, 35(3–4), 186–192.PubMedCrossRef

42.

Vaupel, P., Kallinowski, F., & Okunieff, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Research, 49(23), 6449–6465.PubMed

43.

Classen, J., Belka, C., Paulsen, F., Budach, W., Hoffmann, W., & Bamberg, M. (1998). Radiation-induced gastrointestinal toxicity. Pathophysiology, approaches to treatment and prophylaxis. Strahlentherapie und Onkologie, 174(Suppl 3), 82–84.PubMed

44.

Cionini, L., Becciolini, A., Dalla Palma, L., & De Giuli, G. (1971). Intestinal absorption of radioiodine labeled human serum albumin, mono-iodotyrosine and di-iodotyrosine following abdominal radiation therapy. Acta Radiologica. Therapy, Physics, Biology, 10(3), 341–352.PubMed

45.

Walden, T. L., & Farzaneh, N. K. (1991). Biochemical response of normal tissues to ionizing radiation. In P. H. Gutin, S. A. Liebel, & G. E. Sheline (Eds.) Radiation injury to the nervous system (pp. 17–36). New York: Raven.

46.

Prosser, C. L. (1947). Clinical sequence of physiological effects of ionizing radiation in animals. Radiology, 49, 299–312.

47.

Osborn, G. K., Jones, D. C., & Kimeldorf, D. J. (1964). The effect of age at exposure on radiation-induced polydipsia in the rat. Radiation Research, 23, 119–127.PubMedCrossRef

48.

Pento, J. T., & Kenny, A. D. (1975). The influence of whole-body irradiation on calcium and phosphate homeostasis in the rat. Radiation Research, 63(3), 468–473.PubMedCrossRef

49.

Edelmann, A., & Eversole, W. J. (1950). Changes in antidiuretic activity in rat serum after X-irradiation. American Journal of Physiology, 163, 709.

50.

Goodman, R. D., Lewis, A. E., & Schuck, E. A. (1952). Effects of x-irradiation on gastrointestinal transit and absorption availability. American Journal of Physiology, 169(1), 242–247.PubMed

51.

Dublineau, I., Ksas, B., Joubert, C., Aigueperse, J., Gourmelon, P., & Griffiths, N. M. (2002). Alterations in water and electrolyte absorption in the rat colon following neutron irradiation: Influence of neutron component and irradiation dose. International Journal of Radiation Biology, 78(12), 1127–1138.PubMedCrossRef

52.

Shideler, C. E., Johns, M. E., Cantrell, R. W., Shipe, J. R., Wills, M. R., & Savory, J. (1981). Erythrocyte polyamine determinations in patients with head and neck cancer. Archives of Otolaryngology, 107(12), 752–754.PubMed

53.

Dicker, A. P. (2003). COX-2 inhibitors and cancer therapeutics: Potential roles for inhibitors of COX-2 in combination with cytotoxic therapy: Reports from a symposium held in conjunction with the Radiation Therapy Oncology Group June 2001 Meeting. American Journal of Clinical Oncology, 26(4), S46–S47.PubMedCrossRef

54.

Liang, L., Hu, D., Liu, W., Williams, J. P., Okunieff, P., & Ding, I. (2003). Celecoxib reduces skin damage after radiation: Selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor. American Journal of Clinical Oncology, 26(4), S114–S121.PubMedCrossRef

55.

Hancock, S. L., McDougall, I. R., & Constine, L. S. (1995). Thyroid abnormalities after therapeutic external radiation. International Journal of Radiation Oncology, Biology, Physics, 31(5), 1165–1170.PubMed

56.

Constine, L. S., Woolf, P. D., Cann, D., Mick, G., McCormick, K., Raubertas, R. F., et al. (1993). Hypothalamic–pituitary dysfunction after radiation for brain tumors. New England Journal of Medicine, 328(2), 87–94.PubMedCrossRef

57.

Mitchell, J. B., Biaglow, J. E., & Russo, A. (1988). Role of glutathione and other endogenous thiols in radiation protection. Pharmacology & Therapeutics, 39(1–3), 269–274.CrossRef

58.

Okunieff, P., & Suit, H. D. (1987). Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine fibrosarcomas. Journal of the National Cancer Institute, 79(2), 377–381.PubMed

59.

Delanian, S., Porcher, R., Rudant, J., & Lefaix, J. L. (2005). Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. Journal of Clinical Oncology, 23(34), 8570–8579.PubMedCrossRef

60.

Greenberger, J. S., Epperly, M. W., Gretton, J., Jefferson, M., Nie, S., Bernarding, M., et al. (2003). Radioprotective gene therapy. Current Gene Therapy, 3(3), 183–195.PubMedCrossRef

61.

Greenberger, J. S., & Epperly, M. W. (2007). Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. In Vivo, 21(2), 141–146.PubMed

62.

Belikova, N. A., Jiang, J., Tyurina, Y. Y., Zhao, Q., Epperly, M. W., Greenberger, J., et al. (2007). Cardiolipin-specific peroxidase reactions of cytochrome C in mitochondria during irradiation-induced apoptosis. International Journal of Radiation Oncology, Biology, Physics, 69(1), 176–186.PubMed

63.

Okunieff, P., Li, M., Liu, W., Sun, J., Fenton, B., Zhang, L., et al. (2001). Keratinocyte growth factors radioprotect bowel and bone marrow but not KHT sarcoma. American Journal of Clinical Oncology, 24(5), 491–495.PubMedCrossRef

64.

Paris, F., Fuks, Z., Kang, A., Capodieci, P., Juan, G., Ehleiter, D., et al. (2001). Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science, 293(5528), 293–297.PubMedCrossRef

65.

Okunieff, P., Mester, M., Wang, J., Maddox, T., Gong, X., Tang, D., et al. (1998). In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiation Research, 150(2), 204–211.PubMedCrossRef

66.

Miller, S. M., Ferrarotto, C. L., Vlahovich, S., Wilkins, R. C., Boreham, D. R., & Dolling, J. A. (2007). Canadian Cytogenetic Emergency network (CEN) for biological dosimetry following radiological/nuclear accidents. International Journal of Radiation Biology, 83(7), 471–477.PubMedCrossRef

67.

Blakely, W. F., Salter, C. A., & Prasanna, P. G. (2005). Early-response biological dosimetry-recommended countermeasure enhancements for mass-casualty radiological incidents and terrorism. Health Physics, 89(5), 494–504.PubMedCrossRef

68.

Thierens, H., De Ruyck, K., Vral, A., de Gelder, V., Whitehouse, C. A., Tawn, E. J., et al. (2005). Cytogenetic biodosimetry of an accidental exposure of a radiological worker using multiple assays. Radiation Protection Dosimetry, 113(4), 408–414.PubMedCrossRef

69.

Dertinger, S. D., Miller, R. K., Brewer, K., Smudzin, T., Torous, D. K., Roberts, D. J., et al. (2007). Automated human blood micronucleated reticulocyte measurements for rapid assessment of chromosomal damage. Mutation Research, 626(1–2), 111–119.PubMed

70.

Moiseenko, V. V., Battista, J. J., Hill, R. P., Travis, E. L., & Van Dyk, J. (2000). In-field and out-of-field effects in partial volume lung irradiation in rodents: Possible correlation between early DNA damage and functional endpoints. International Journal of Radiation Oncology, Biology, Physics, 48(5), 1539–1548.PubMed

71.

Swartz, H. M., Iwasaki, A., Walczak, T., Demidenko, E., Salikhov, I., Khan, N., et al. (2006). In vivo EPR dosimetry to quantify exposures to clinically significant doses of ionising radiation. Radiation Protection Dosimetry, 120(1–4), 163–170.PubMedCrossRef

72.

Anscher, M. S., Peters, W. P., Reisenbichler, H., Petros, W. P., & Jirtle, R. L. (1993). Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New England Journal of Medicine, 328(22), 1592–1598.PubMedCrossRef

73.

Zhao, L., Sheldon, K., Chen, M., Yin, M. S., Hayman, J. A., Kalemkerian, G. P., et al. (2007). The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer, 59(2), 232–239 Sep 28.PubMedCrossRef

74.

Bentzen, S. M., Skoczylas, J. Z., Overgaard, M., & Overgaard, J. (1996). Radiotherapy-related lung fibrosis enhanced by tamoxifen. Journal of the National Cancer Institute, 88(13), 918–922.PubMedCrossRef

75.

Marchetti, F., Coleman, M. A., Jones, I. M., & Wyrobek, A. J. (2006). Candidate protein biodosimeters of human exposure to ionizing radiation. International Journal of Radiation Biology, 82(9), 605–639.PubMedCrossRef

76.

Chaudhry, M. A. (2006). Bystander effect: Biological endpoints and microarray analysis. Mutation Research, 597(1–2), 98–112.PubMed

77.

Rieger, K. E., Hong, W. J., Tusher, V. G., Tang, J., Tibshirani, R., & Chu, G. (2004). Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 101(17), 6635–6640.PubMedCrossRef

78.

Quarmby, S., West, C., Magee, B., Stewart, A., Hunter, R., & Kumar, S. (2002). Differential expression of cytokine genes in fibroblasts derived from skin biopsies of patients who developed minimal or severe normal tissue damage after radiotherapy. Radiation Research, 157(3), 243–248.PubMedCrossRef

79.

Ho, A. Y., Atencio, D. P., Peters, S., Stock, R. G., Formenti, S. C., Cesaretti, J. A., et al. (2006). Genetic predictors of adverse radiotherapy effects: The Gene-PARE project. International Journal of Radiation Oncology, Biology, Physics, 65(3), 646–655.PubMed

80.

Mayo, M. S., Gajewski, B. J., & Morris, J. S. (2006). Some statistical issues in microarray gene expression data. Radiation Research, 165(6), 745–748.PubMedCrossRef

81.

Williams, J. R., Zhang, Y., Russell, J., Koch, C., & Little, J. B. (2007). Human tumor cells segregate into radiosensitivity groups that associate with ATM and TP53 status. Acta Oncológica, 46(5), 628–638.PubMedCrossRef

82.

Chen, Y., Williams, J., Ding, I., Hernady, E., Liu, W., Smudzin, T., et al. (2002). Radiation pneumonitis and early circulatory cytokine markers. Seminars in Radiation Oncology, 12(1 Suppl 1), 26–33.PubMedCrossRef

83.

Andreassen, C. N., Alsner, J., Overgaard, M., Sorensen, F. B., & Overgaard, J. (2006). Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM—A study based on DNA from formalin fixed paraffin embedded tissue samples. International Journal of Radiation Biology, 82(8), 577–586.PubMedCrossRef

Titel: Molecular markers of radiation-related normal tissue toxicity
verfasst von: Paul Okunieff
Yuhchyau Chen
David J. Maguire
Amy K. Huser
Publikationsdatum: 01.09.2008
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9138-7

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Molecular markers of radiation-related normal tissue toxicity

Abstract

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

Clinical target promiscuity: lessons from ras molecular trials

Pancreatic cancer: from molecular pathogenesis to targeted therapy

Clinical biomarkers of kinase activity: examples from EGFR inhibition trials

Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials

Biographical sketch—Dr. Robert Bristow

Preface

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie